Bryan Johnson’s protocol is the headline, but the real story is diminishing returns

Bryan Johnson’s protocol is the headline, but the real story is diminishing returns

Bryan Johnson reportedly spends around $2 million a year on his anti-aging protocol: a full-time clinical team, continuous biomarker monitoring, quarterly MRIs, and chef-prepared meals engineered down to the gram. Outside estimates suggest a person willing to spend $5,000 to $20,000 over a season can capture roughly 80% of what that $2 million delivers. The brutal part is the gap: the last 20% costs somewhere between 100 and 400 times more than the first 80%.

Gobble's Take: Longevity has a price tag, and the last few percentage points are where the luxury tax starts pretending to be science.
Source: Perplexity Search (community news)

The boring stuff keeps winning: fitness, resistance training, sleep

Cardiorespiratory fitness has one of the clearest signals in the field: a 2022 analysis in the British Journal of Sports Medicine found that each one-unit increase in a standard fitness measure called METs was associated with roughly a 13% reduction in all-cause mortality. The same pack puts resistance training and adequate sleep in the same tier: unglamorous, essentially free, and backed by decades of evidence. The message is annoyingly simple, which is probably why people keep trying to outrun it with shinier protocols.

Gobble's Take: The least glamorous habits still look like the strongest deal in the entire longevity aisle.
Source: Perplexity Search (community news)

Gene therapies are moving from theory toward the clinic’s front door

So far, gene therapy has been approved by the U.S. FDA for only a couple of applications like rare inherited diseases and blood cancer. But more than 2,000 clinical trials were taking place in 2023, with 200 already at phase 3. The pack also points to upcoming gene therapies that could be approved in the months to come in the United States and Europe, targeting everything from sickle cell disease and hemophilia to metastatic skin cancer.

Gobble's Take: This is where “future medicine” stops being a slogan and starts looking like paperwork with a lab coat on.
Source: Perplexity Search (community news)

Partial reprogramming is the shiny edge — and the safety warning is built in

Shinya Yamanaka and colleagues discovered four genes — Oct4, Sox2, Klf4, c-Myc — later called the Yamanaka factors, and that work earned the 2012 Nobel Prize in Physiology or Medicine. The pack says Life Biosciences injected three genes — OCT4, SOX2, KLF4 — into the eyes of glaucoma patients through a viral vector, not to treat glaucoma, but to make aged retinal nerve cells become young again. The same source is more specific about the risk: press the reset button without knowing the right measure and the cell may completely lose its memory — forgetting whether it is a skin cell, a nerve cell, or a liver cell — which can cause it to turn into a teratoma, a chaotic tumor of disordered growth.

Gobble's Take: Rejuvenation sounds elegant right up until biology reminds you it can also become chaos with a better branding team.
Source: Perplexity Search (community news)

In Case You Missed It

Yesterday's top stories:

• The silent fire of ageing